Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
24/7 Market News Lunch Break 25 Sept 2023 September 25, 2023
24/7 Market News Snapshot 25 Sept 2023 September 25, 2023
ESS Tech Collaborates with Honeywell to Accelerate Iron Flow Battery Energy Storage Systems Deployment September 25, 2023
TransCode Therapeutics’ Lead Therapeutic Candidate, TTX-MC138, effectively engaged its Target September 25, 2023
Vapotherm HVNI technology outperforms standard oxygen therapy for treatment of acute asthma in children according to Pilot Study September 25, 2023
Next
Prev

(NASDAQ: IFRX) InflaxRx N.V. shares are up more than 11% in pre-market trading on more than 3200 trades and increasing volume. Shares are $1.58 and volume is increasing on FDA news.

  • Jul 6, 2022 at 7:25 AM

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

https://www.globenewswire.com/news-release/2022/07/06/2474834/0/en/InflaRx-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Ulcerative-Pyoderma-Gangrenosum.html

RelatedNews

Page 1 of 3
123

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.